Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adma Biologics (ADMA) Capital Leases (2016 - 2021)

Adma Biologics (ADMA) has disclosed Capital Leases for 10 consecutive years, with $6.4 million as the latest value for Q1 2021.

  • For the quarter ending Q1 2021, Capital Leases rose 250.48% year-over-year to $6.4 million, compared with a TTM value of $6.4 million through Mar 2021, up 250.48%, and an annual FY2020 reading of $4.3 million, up 232.79% over the prior year.
  • Capital Leases was $6.4 million for Q1 2021 at Adma Biologics, up from $4.3 million in the prior quarter.
  • Across five years, Capital Leases topped out at $6.4 million in Q1 2021 and bottomed at $15319.0 in Q1 2017.
  • Average Capital Leases over 5 years is $1.8 million, with a median of $1.4 million recorded in 2019.
  • The sharpest move saw Capital Leases skyrocketed 993.69% in 2019, then increased 25.33% in 2020.
  • Year by year, Capital Leases stood at $15319.0 in 2017, then surged by 677.34% to $119080.0 in 2018, then surged by 993.69% to $1.3 million in 2019, then surged by 232.79% to $4.3 million in 2020, then surged by 48.12% to $6.4 million in 2021.
  • Business Quant data shows Capital Leases for ADMA at $6.4 million in Q1 2021, $4.3 million in Q4 2020, and $2.9 million in Q3 2020.